Peer Review Plan for the Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings

Title: Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings

Anticipated Date of Dissemination: January 2018

Subject: Hazardous Drug Exposure in Healthcare Settings

Purpose: To describe the internal practices used by NIOSH to add or remove pharmaceutical substances to/from the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings.

Agency contact for information:

Timing of Review: January 29, 2018 – February 28, 2018

Primary Disciplines or Expertise Needed for Review: pharmacy, nursing, pharmacology, occupational health, toxicology, veterinary medicine

Type of Review: Individual letters

Number of Reviewers: 4 — 10

Reviewers Selected by: CDC/NIOSH

Public Nominations Requested for Review Panel: No

Opportunities for the Public to Comment: Yes, Provide comments on this plan via email to the Agency contact identified above

Peer Reviewers Provided with Public Comments Before Their Review: No

Peer Reviewers

Michael O. Childress DVM, MS, DACVIM
Associate Professor of Comparative Oncology
Dept Veterinary Clinical Sciences
Purdue College of Veterinary Medicine

Chun-Yip Hon PhD, CPHI(C), CIH, CRSP
Associate Professor
School of Occupational and Public Health
Ryerson University

Melissa McDiarmid, MD, MPH, DABT
Professor of Medicine and Epidemiology & Public Health
Director, Division of Occupational & Environmental Medicine
University of Maryland School of Medicine

AnnMarie Walton, PhD
Assistant Professor, School of Nursing
Duke University

Charge to Peer Reviewers

  • Does the draft policy and procedures clearly describe the process used by NIOSH to screen and evaluate drugs?
  • Are the screening and evaluation categorization processes described by the draft policy and procedures scientifically sound?
  • Is the set of information sources used for classifying drugs sufficient to identify relevant hazards?  Are there other information sources that should be included?
  • Is the threshold of information required to move from the screening process to the full evaluation process clearly described?  Is the information threshold scientifically sound?
  • Is the reconsideration process for addition or deletion of a drug to/from the hazardous drug list adequately described?
  • Are there any issues not considered by the charge questions that should addressed?
Page last reviewed: January 5, 2018